<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-Q2EQW9GK</identifier><date>2012</date><creator>Langerholc, Tomaž</creator><relation>documents/doc/Q/URN_NBN_SI_doc-Q2EQW9GK_001.htm</relation><relation>documents/doc/Q/URN_NBN_SI_doc-Q2EQW9GK_001.pdf</relation><relation>documents/doc/Q/URN_NBN_SI_doc-Q2EQW9GK_001.txt</relation><format format_type="issue">6</format><format format_type="volume">81</format><format format_type="type">article</format><format format_type="extent">str. 493-499</format><identifier identifier_type="ISSN">1318-0347</identifier><identifier identifier_type="COBISSID">263303936</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-Q2EQW9GK</identifier><language>slv</language><publisher>Slovensko zdravniško društvo</publisher><source>Zdravniški vestnik</source><rights>BY-NC</rights><subject language_type_id="slv">protitumorska zdravila</subject><subject language_type_id="slv">rak (medicina)</subject><subject language_type_id="slv">telomeraza</subject><title>Encim telomeraza - tarča za prihodnja zdravila?</title><title>Telomerase - future drug target enzyme?</title></Record>